- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03681600
Observatory of the Quality of Surgical Procedures for Digestive Cancers (Obchir)
Observatory of the Quality of Surgical Procedures for Digestive Cancers: Pilot Project.
Surgery for digestive cancers is managed according to quality standards, validated by the scientific community. Despite the diffusion of these standards through the benchmarks of good practice, the results of the surgery remain disparate.
In many countries, this "inequality of opportunity" has justified the establishment of quality assurance systems to measure the results of surgery for one or more localizations of digestive cancer.
These surgical audit experiments have shown a positive, rapid and cost-effective impact on complication rates, recurrence rates and overall survival even in the absence of interventional measures. The data collected also helped to improve the management of subgroups of patients usually excluded from clinical trials.
In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of a quality assurance system with the introduction of a system for monitoring and evaluating the care of patients. This pilot project is part of this framework, for the group of patients who are candidates for surgery for digestive cancers.
Studienübersicht
Status
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Oujda, Marokko
- Regional center of oncology, surgical department
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department A
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department C
-
-
Please Enter The State Or Province
-
Rabat, Please Enter The State Or Province, Marokko, 10100
- National Institut of Oncology, Surgical oncology department
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- patients operated for a digestive cancer, proven or suspected, in a curative or palliative intent In elective situation: inclusion from surgery programming In emergent situation: inclusion no later than 72 hours after surgery
- Cancer proven or suspected in the following digestive tract: colon, appendix, anus, rectum, esophagus, stomach, eso-gastric junction, bile ducts, ampulla of Vater , pancreas, duodenum, small intestine and liver.
- Patient willing and able to agree to participate in the study
Exclusion Criteria:
Patient whose surgical intervention is indicated for:
- a condition that is not a digestive tract cancer, including whether retrospectively surgical exploration and / or histological examination reveals digestive localization cancer
- proven or suspected cancer of non-digestive location
- a proven or suspected cancer of peritoneal localization
- Patient whose surgical intervention is indicated for a progressive disease or a local recurrence proven or suspected of a digestive localization cancer having already been the resected (with the exception of situations of iterative liver resection for liver metastasis hepatic and recovery of the tumor bed after the discovery of vesicular cancer on cholecystectomy specimen)
- Patients whose intervention is for diagnostic purposes without any curative or palliative intention
- Patients whose surgery is a liver transplant
- Patients whose surgical intervention is local destruction (radiofrequency, microwaves) exclusively by percutaneous approach (without laparotomy or laparoscopy)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
90-day Mortality rate
Zeitfenster: 90 days from surgery
|
Death within 90 days of surgical procedure
|
90 days from surgery
|
|
90-day Complication rate
Zeitfenster: 90 days from surgery
|
Defined with by Clavien-Dindo grade I to IV within90 days of surgical procedure
|
90 days from surgery
|
|
3-year Overall survival
Zeitfenster: from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
Overall survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
|
3-year disease free survival
Zeitfenster: from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Disease free survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Treatment decisions made within multidisciplinary team meeting / tumour board
Zeitfenster: Prior to surgery
|
For every localization
|
Prior to surgery
|
|
Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging
Zeitfenster: Prior to surgery
|
For every localization
|
Prior to surgery
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Amine Benkabbou, Pr, Moroccan Society of Surgery
- Hauptermittler: Raouf Mohsine, Pr, National institut of oncology
- Hauptermittler: Abdelmalek Hrora, Pr, Moroccan Society of Surgery
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MoroccanSS
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .